Semaglutide's exclusivity period will last until April 2027.

Semaglutide isn't going generic anytime soon. The exclusivity period for semaglutide runs through April 2027, locking out generic and biosimilar versions for now. If you’re tracking the research compound market, that’s a big deal. Semaglutide has attracted a lot of attention for its peptide structure and unique mechanism of action. But until the exclusivity window closes, only the original manufacturer controls supply.

Why does this matter for researchers? Access, pricing, and sourcing are all tied to exclusivity. With no generics in play, researchers looking to study semaglutide are limited to approved sources. That keeps the research ecosystem tightly managed for now.

Key takeaway:

This timeline shapes both lab planning and budget decisions. If you’re mapping out future projects involving this peptide, mark April 2027 on your calendar—generic supply could open up the market, bring down costs, and increase sourcing flexibility. Until then, anyone running semaglutide studies will need to stick with current suppliers. Curious about sourcing or comparing vendors? Check out the vendor directory.

Bottom line: semaglutide’s exclusivity keeps the peptide market straightforward but limited for the next few years. Researchers will want to keep an eye on the calendar—and plan accordingly.